Zhentang Lao

Zhentang Lao

Auto-generated profile, based on publicly available information

Zhentang Lao

Department of Haematology, Singapore General Hospital, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2016 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
YCY Chen
Y Chen
MOM Ooi
M Ooi
SLSoh Fong Lim
Soh Fong Lim
ALA Lin
A Lin
JLJ Lee
J Lee
SGS K Gopalakrishnan
S K Gopalakrishnan
Thrombotic microangiopathy during carfilzomib use: case series in Singapore

13 January 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
XRXue-Bin Ran
Xue-Bin Ran
LDLing-Wen Ding
Ling-Wen Ding
QSQiaoyang Sun
Qiaoyang Sun
Henry YangHenry Yang
Henry Yang
JSJonathan W. Said
Jonathan W. Said
HKH. Phillip Koeffler
H. Phillip Koeffler
Despite the remarkable clinical responses achieved with immune checkpoint blockade therapy, the response rate is relatively low and only a subset of patients can benefit from the treatment. Aberrant RNA accumulation can mediate IFN signaling and stimulate an immune response, suggesting that targeting RNA decay machinery might sensitize tumor cells to immunotherapy. With this in mind, we identified an RNA exoribonuclease, XRN1, as a potential therapeutic target to suppress RNA decay and stimulate antitumor immunity. Silencing of XRN1 suppressed tumor growth in syngeneic immunocompetent mice and potentiated immunotherapy efficacy, while silencing of XRN1 alone did not affect tumor growth in immunodeficient mice. Mechanistically, XRN1 depletion activated IFN signaling and the viral defense pathway; both pathways play determinant roles in regulating immune evasion. Aberrant RNA-sensing signaling proteins (RIG-I/MAVS) mediated the expression of IFN genes, as depletion of each of them blunted the elevation of antiviral/IFN signaling in XRN1-silenced cells. Analysis of pan-cancer CRISPR-screening data indicated that IFN signaling triggered by XRN1 silencing is a common phenomenon, suggesting that the effect of XRN1 silencing may be extended to multiple types of cancers. Overall, XRN1 depletion triggers aberrant RNA-mediated IFN signaling, highlighting the importance of the aberrant RNA-sensing pathway in regulating immune responses. These findings provide the molecular rationale for developing XRN1 inhibitors and exploring their potential clinical application in combination with cancer immunotherapy. Significance: Targeting XRN1 activates an intracellular innate immune response mediated by RNA-sensing signaling and potentiates cancer immunotherapy efficacy, suggesting inhibition of RNA decay machinery as a novel strategy for cancer treatment.

2 March 2017 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
LDLing-Wen Ding
Ling-Wen Ding
QSQiao-Yang Sun
Qiao-Yang Sun
AMAnand Mayakonda
Anand Mayakonda
KTKar-Tong Tan
Kar-Tong Tan
WCWenwen Chien
Wenwen Chien
HKH. Phillip Koeffler
H. Phillip Koeffler
Relapsed acute lymphoblastic leukemia (ALL) is the leading cause of deaths of childhood cancer. Although relapse usually happens in the bone marrow, extramedullary relapse occasionally occurs including either the central nervous system or testis (<1–2%). We selected two pediatric ALL patients who experienced testicular relapse and interrogated their leukemic cells with exome sequencing. The sequencing results and clonality analyses suggest that relapse of patient D483 directly evolved from the leukemic clone at diagnosis which survived chemotherapy. In contrast, relapse leukemia cells (both bone marrow and testis) of patient D727 were likely derived from a common ancestral clone, and testicular relapse likely arose independently from the bone marrow relapsed leukemia. Our findings decipher the mutational spectra and shed light on the clonal evolution of two cases of pediatric ALL with testicular relapse. Presence of CREBBP/NT5C2 mutations suggests that a personalized therapeutic approach should be applied to these two patients.

29 June 2010 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
DTDaryl Tan
Daryl Tan
GTGerrard Teoh
Gerrard Teoh
LLL.C. Lau
L.C. Lau
ALAlvin Lim
Alvin Lim
TLT.H. Lim
T.H. Lim
YGY.T. Goh
Y.T. Goh
Multiple myeloma is clinically heterogeneous and risk stratification is vital for prognostication and informing treatment decisions. As bortezomib is able to overcome several high‐risk features of myeloma, the validity of conventional risk‐stratification and prognostication systems needs to be reevaluated. We study the survival data of 261 previously untreated myeloma patients managed at our institution, where bortezomib became available from 2004 for the treatment of relapse disease. Patient and disease characteristics, and survival data were evaluated overall, and with respect to bortezomib exposure. Overall, the international staging system (ISS), metaphase karyotyping and interphase fluorescence in situ hybridization (FISH) were discerning of survival outcomes, where the median for the entire cohort was 5.2 years. However, when stratified by bortezomib exposure, only metaphase karyotyping was still discriminating of long‐term prognosis. The presence of an abnormal nonhyperdiploid karyotype overrides all other clinical and laboratory parameters in predicting for a worse outcome on multivariate analysis (median survival 2.6 years,P= 0.001), suggesting that bortezomib used at relapse is better able to overcome adverse risk related to high tumor burden (as measured by the ISS) than adverse cytogenetics on conventional karyotyping. Metaphase karyotyping provides additional prognostic information on tumor kinetics where the presence of a normal diploid karyotype in the absence of any high‐risk FISH markers correlated with superior survival and could act as a surrogate for lower plasma cell proliferation. Am. J. Hematol., 2010.

1 October 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KTKar-Tong Tan
Kar-Tong Tan
LDLing-Wen Ding
Ling-Wen Ding
QSQiao-Yang Sun
Qiao-Yang Sun
ZLZhen-Tang Lao
Zhen-Tang Lao
WCWenwen Chien
Wenwen Chien
HKH. Phillip Koeffler
H. Phillip Koeffler
Clonal VDJ rearrangement of B/T cell receptors (B/TCRs) occurring during B/T lymphocyte development has been used as a marker to track the clonality of B/T cell populations. We systematically profiled the B/T cell receptor repertoire of 936 cancer cell lines across a variety of cancer types as well as 462 Epstein-Barr Virus (EBV) transformed normal B lymphocyte lines using RNA sequencing data. Rearranged B/TCRs were readily detected in cell lines derived from lymphocytes, and subclonality or potential biclonality were found in a number of blood cancer cell lines. Clonal BCR/TCR rearrangements were detected in several blast phase CML lines and unexpectedly, one gastric cancer cell line (KE-97), reflecting a lymphoid origin of these cells. Notably, clonality was highly prevalent in EBV transformed B lymphocytes, suggesting either transformation only occurred in a few B cells or those with a growth advantage dominated the transformed population through clonal evolution. Our analysis reveals the complexity and heterogeneity of the BCR/TCR rearrangement repertoire and provides a unique insight into the clonality of lymphocyte derived cell lines.

28 December 2014 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ZLZhentang Lao
Zhentang Lao
RYRichard Yiu
Richard Yiu
GWGee Chuan Wong
Gee Chuan Wong
AHAloysius Ho
Aloysius Ho